Table of Contents - WOC 2012

More documents

Recommendations

Info

WOC2012 Abstract Book PO-GLA-19 Relationship between macular ganglion cell complex thickness and visual acuity in glaucoma patients Maezawa Chikusa (1) , Miyahara Teruyoshi (1) , Yamamoto Yuuka (1) , Murata Toshinori (1) 1. Department of Ophthalmology PURPOSE: To investigate the relationship between the thicknesses of the macular ganglion cell complex (mGCC) and the visual acuity in glaucoma. Methods: One hundred nine eyes of 71 consecutive patients with glaucoma were?studied. The patients with media opacity or retinal disorder besides glaucoma were excluded from analysis. The mGCC of 4 sectors located within 1.5 mm of the fovea?(temporal superior, temporal inferior, nasal superior, and nasal inferior) was measured by Stratus optical coherence tomography RS- 3000 (Nidek, Japan). The relation between best corrected visual acuity and mean or maximum thicknesses of mGCC was evaluated. Results: The Spearman coefficient values (R) of correlation between the best- corrected vision (logarithm of the minimum angle of resolution, log MAR) and the mean and maximum thicknesses of mGCC were 0.454 (P
PO-GLA-23 Evaluation Of Surgical Treatment of Trabectome In Japanese Patients With Primary Open-Angle Glaucoma Ichikawa Kazuo (1) , Hara Shuya (1) , Watanabe Mitsunori (1) , Maeda Masahiro (2) 1. Social Insurance Chukyo Hospital 2. Gifu Red Cross Hospital Purpose: To evaluate the surgical treatment of Trabectome with or without cataract surgery in adult Japanese patients with primary open-angle glaucoma (POAG). Methods: Surgical device, Trabectome, was evaluated in retrospective case series involving 112 eyes of adult Japanese POAG patients with or without previous surgery or laser treatment (43 cases of Trabectome and 69 cases of Trabectome with phaco). Goldmann applanation intraocular pressure (IOP), adjunctive medications, corneal endothelial cell density, and best corrected visual acuity were measured before and after surgery. Intraoperative and postoperative adverse events were also tabulated. Results: Mean pre-operative IOP of Trabectome and Trabectome with phaco decreased from 26.6±8.7 mmHg and 21.5±5.5 to 16.1±3.8 mmHg and 16.9±2.9 respectively by 12 months after surgery [N=18 and 33]. The number of adjunctive medications of Trabectome and Trabectome with phaco decreased from 3.7 ± 1.4 and 2.6±1.3 to 2.7±0.8 and 1.8±1.5 respectively. Intraoperative blood reflux occurred in 100% of cases. No vision-threatening complications such as choroidal effusion, choroidal hemorrhage, or infection occurred. 9 cases received surgical re-intervention. No significant change of endothelial cell density was recognized. Conclusion: Trabectome surgical treatment is an effective and safe alternative method of lowering IOP in POAG today. PO-GLA-24 Canaloplasty after failed trabeculectomy Jasinskas Vytautas (1) 1. Eye Department of Lithuanian University of Medical Sciences Purpose.To evaluate IOP lowering effect of canaloplasty after Failed trabeculectomy Methods. Canaloplasty after previously unsuccessful trabeculectomy(tr) was performed in 6 eyes. Two aproeches were applied.I. In eyes with tr. zone involving Shlems canal(ShC) procedure was performed in previous surgery zone by enlarging superfitial scleral flap +1mm to all sides.deep scleral flap overhelmed tr zone+0,5mm each side over ShC and descemet membrane was unroofed.10-0 prolene suture was inserted into ShC with help of microcatheter,streched and tied(3eyes).II. In cases with tr zone free of ShC(diagnosed during gonioscopy) regular canaloplasty prosedure in Virgin area was performed (3 eyes). follow up 1 to 16 months. results. before canaloplasty mean IOP was 21,17±6,6mmHg.after the procedure IOP decreased in all cases and after 1 months was 10,52±8,04 mmHg. In group I manifested complications typical to tr (shallow anterior chamber, choroid detachment)(2 eyes). Conclusions. Canaloplasty as promising alternative procedure maybe utilized after failed filtering glaucoma surgery in selective cases. WOC2012 Abstract Book PO-GLA-25 Comparison of cytotoxicity induced on cultured human conjunctival cells by travoprost with benzalkonium chloride and travoprost with Polyquad® Pérez-Roca Fernando (1) , Rodrigo Morales Esther (1) , Ramos López Juan Francisco (1) , Garzón Ingrid (2) , González-Andrades Miguel (3) 1. University Hospital Virgen de las Nieves 2. University of Granada 3. University Hospital San Cecilio Objectives To study the cytotoxicity effects on human conjunctival cells by travoprost with benzalkonium chloride as preservative (BAK) and travoprost with Polyquad® a polycationic polymer as a novel preservative used in glaucoma medical treatment Methods In one hand, primary cell cultures of human conjunctival cells were stablished from surgical biopsies of patients without ocular surface disease. In another hand, we investigated the cytotoxic effects by sequential dilutions of travoprost with BAK and travoprost with Polyquad®. For these aim, WST-1 assay, a non-radioactive colorimetric quantitative method that measure mitochondrial enzyme activity were performed at 5, 30 minutes and 6 hours of exposure. Results Our results demonstrated that both travoprost with BAK and travoprost with polyquad® produce a dose-dependent toxicity effects. Although, travoprost with polyquad® appears to be less harmful in the cultured human conjunctival cells maintaining a higher metabolic rate were higher concentrations were used in all times of ex vivo exposure. Conclusion This work demonstrated that travoprost with Polyquad®, a novel preservative used in glaucoma medical treatment, has lower ocular toxicity in human conjunctival cells ex vivo. PO-GLA-26 Intraoperative use of Provisc in primary trabeculectomy with adjunctive low-dosage mitomycin C in advanced glaucoma Kasimov Elmar (1) , Aghayeva Fidan (1) 1. National Centre of Ophthalmology named after academician Zarifa Aliyeva Purpose: To evaluate the clinical efficacy and the incidence of early complications after intraoperative use of Provisc (1% sodium hyaluronate) in primary trabeculectomy with low-dosage mitomycin C (MMC, 0.2mq/ml for 2 min) in advanced glaucoma. Methods: This prospective study included 18 patients (18 eyes) with medically uncontrolled advanced glaucoma (MD>-15dB; 5 cases of primary open-angle, 13 cases of pseudoexfoliative glaucoma) who underwent injection of Provisc below the scleral flap, into the anterior chamber to prevent early overfiltration after filtering surgery. Results: Mean IOP decreased from 32mmHg preoperatively to 13mmHg by postoperative month 8 (the mean follow-up). The visual acuity remained stable in 15 patients, in 3 patients visual acuity was reduced due to cataract progression. The postoperative complications included transient hypotony (3 eyes, 16,7%), 1 case of hypotony (5,6%) was associated with anterior chamber shallowing; hyphema (2 eyes, 11,1%). The mean preoperative number of antiglaucoma medications was 2,2; only 2 eyes (11,1%) required antiglaucoma medications postoperatively. Avascular bleb (grade 2) was encountered in 4 eyes (22,2%). Conclusions: Intraoperative use of Provisc along with low-dosage MMC improve the outcome of primary trabeculectomy with a low incidence of complications in the short-term period in patients with advanced glaucoma requiring low final IOP. 523
Page 3 and 4:
Abstracts - Thursday, 16 February B
Page 5 and 6:
History of Ophthalmology 2 ........
Page 7 and 8:
Clinicopathological Correlation: Re
Page 9 and 10:
Basic: Intraocular Pressure in Clin
Page 11 and 12:
Congenital and Pediatric Cataracts
Page 13 and 14:
Free Paper: Glaucoma Thu 16 Feb 9:0
Page 15 and 16:
FP-GLA-TH 07 (9) Phacoemulsificatio
Page 17 and 18:
FP-REF-TH 08 (7) Ectasia Risk Score
Page 19 and 20:
FP-RET-TH 09 (4) Ranibizumab in Age
Page 21 and 22:
FP-PED-TH 10 (2) Multifocal Electro
Page 23 and 24:
FP-PED-TH 10 (10) Unilateral Amblyo
Page 25 and 26:
FP-OCP-TH 11 (8) Transcanalicular E
Page 27 and 28:
FP-CAT-TH 12 (6) Radiofrequency Dia
Page 29 and 30:
FP-RET-TH 13 (4) Outcome of Penetra
Page 31 and 32:
Intermediate Thu 16 Feb 13:00 - 14:
Page 33 and 34:
IS-RET-TH 16 (2) Polypoidal Choroid
Page 35 and 36:
IS-CAT-TH 19 (6) Phaco Post Intacs,
Page 37 and 38:
FP-GLA-TH 20 (9) The Electroretinog
Page 39 and 40:
FP-REF-TH 21 (8) Outcomes of Angle-
Page 41 and 42:
FP-RET-TH 22 (5) Advantages of Subt
Page 43 and 44:
FP-PED-TH 23 (4) Primary Congenital
Page 45 and 46:
IS-SOS-TH 24 (2) Pupils Bosely Thom
Page 47 and 48:
FP-OCP-TH 25 (9) Bilateral Ritual E
Page 49 and 50:
FP-CAT-TH 26 (8) Objective Measurem
Page 51 and 52:
FP-RET-TH 27 (6) Imaging Retinal Pi
Page 53 and 54:
High Refractive Errors: What Is Wor
Page 55 and 56:
IS-PED-TH 31 (4) Education Signific
Page 57 and 58:
IS-CAT-TH 33 (20) IOL Exchange for
Page 59 and 60:
FP-GLA-TH 34 (10) Comparison of ICa
Page 61 and 62:
FP-REF-TH 35 (9) Orbscan as a Prere
Page 63 and 64:
FP-RET-TH 36 (7) Continuous Monthly
Page 65 and 66:
FP-PED-TH 37 (4) Long Term Visual O
Page 67 and 68:
Free Paper: Oculoplastics, Lacrimal
Page 69 and 70:
FP-OCP-TH 39 (9) In Vivo Efficacy o
Page 71 and 72:
FP-CAT-TH 40 (9) First Results Afte
Page 73 and 74:
FP-RET-TH 41 (6) Outcomes of Epiret
Page 75 and 76:
IS-REF-TH 43 (2) Scheimpflug-based
Page 77 and 78:
IS-OCP-TH 46 (2) Enucleation in the
Page 79 and 80:
FP-GLA-TH 48 (4) Comparison Between
Page 81 and 82:
Free Paper: Refractive Surgery Thu
Page 83 and 84:
FP-REF-TH 49 (9) Intraoperative Pre
Page 85 and 86:
FP-RET-TH 50 (6) A Study on the Pre
Page 87 and 88:
FP-PED-TH 51 (7) Acute Retinal Necr
Page 89 and 90:
FP-CAT-TH 52 (5) Visual Outcome Aft
Page 91 and 92:
FP-OCP-TH 53 (5) Solitary Fibrous T
Page 93 and 94:
FP-CAT-TH 54 (5) Advantages of Usin
Page 95 and 96:
FP-RET-TH 55 (5) Correlation of Spe
Page 97 and 98:
Abstracts Friday 17 February
Page 99 and 100:
IS-GLA-FR 57 (3) Canaloplasty Gries
Page 101 and 102:
FP-RET-FR 60 (2) Ocular Primary Bla
Page 103 and 104:
FP-RET-FR 60 (10) The Effect of Com
Page 105 and 106:
IS-STR-FR 63 (2) Dysthyroid Myopath
Page 107 and 108:
Free Paper: Pathology Fri 17 Feb 8:
Page 109 and 110:
FP-PAT-FR 66 (10) Relative Contribu
Page 111 and 112:
Epidemiology of Uveitis and Related
Page 113 and 114:
FP-REF-FR 71 (8) Management of Extr
Page 115 and 116:
FP-COR-FR 72 (5) CFTR is Functional
Page 117 and 118:
FP-ONC-FR 73 (5) Criteria for Posto
Page 119 and 120:
FP-CAT-FR 74 (2) Anticardiolipin An
Page 121 and 122:
Trabectome Surgery for Infantile Gl
Page 123 and 124:
Keratoconus and Ectatic Disorders:
Page 125 and 126:
The Hot Orbit Fri 17 Feb 10:30 - 12
Page 127 and 128:
IS-ONC-FR 89 (3) Adjuvant Therapy i
Page 129 and 130:
Contact Lenses 2 Fri 17 Feb 10:30 -
Page 131 and 132:
IS-PER-FR 96 (5) Secondary Glaucoma
Page 133 and 134:
FP-COR-FR 97 (8) Saving Sight in Co
Page 135 and 136:
FP-RET-FR 98 (5) Intravitreal (IVT)
Page 137 and 138:
FP-PHA-FR 99 (2) A New Therapeutic
Page 139 and 140:
Difficult Situations in Phacoemulsi
Page 141 and 142:
Current Trends in Corneal Replaceme
Page 143 and 144:
IS-OCP-FR 110 (2) Synkinetic Ptosis
Page 145 and 146:
IS-ONC-FR 113 (3) Emerging Molecula
Page 147 and 148:
IS-WFS-FR 116 (4) Report from the A
Page 149 and 150:
Free Paper: Strabismus Fri 17 Feb 1
Page 151 and 152:
FP-STR-FR 121 (9) Adjustable Squint
Page 153 and 154:
FP-RET-FR 122 (7) Intravitreal Beva
Page 155 and 156:
FP-CAT-FR 123 (4) Patient Satisfact
Page 157 and 158:
Strategies for Very Dense Nuclei an
Page 159 and 160:
IS-VID-FR 130 (2) Phaco-trabeculect
Page 161 and 162:
IS-RET-FR 133 (5) Choroidal Surgery
Page 163 and 164:
IS-CAT-FR 136 (3) Difractive vs. Re
Page 165 and 166:
IS-TEC-FR 139 (2) Future Therapeuti
Page 167 and 168:
IS-SOS-FR 142 (2) When to Refer the
Page 169 and 170:
Free Paper: External Eye Disease, C
Page 171 and 172:
FP-COR-FR 146 (10) Repeatability an
Page 173 and 174:
FP-RET-FR 147 (7) Sutureless 23 G V
Page 175 and 176:
FP-UVE-FR 148 (4) Clinical Patterns
Page 177 and 178:
Strategies for Very Dense Nuclei an
Page 179 and 180:
Abstracts Saturday 18 February
Page 181 and 182:
IS-TRA-SA 158 (2) Pearls and Pitfal
Page 183 and 184:
IS-CAT-SA 161 (2) Cataract Surgery
Page 185 and 186:
Assessment of Clinical Skills of Re
Page 187 and 188:
IS-EVI-SA 168 (4) Summary of Eviden
Page 189 and 190:
FP-PED-SA 171 (4) Optical Iridectom
Page 191 and 192:
FP-ONC-SA 172 (3) Conjunctival Squa
Page 193 and 194:
FP-CAT-SA 173 (2) The Visual and Re
Page 195 and 196:
How to Write a Scientific Paper Sat
Page 197 and 198:
Novel Mechanisms and Risk Factors f
Page 199 and 200:
IS-RET-SA 183 (6) Intravascular Thr
Page 201 and 202:
IS-CAT-SA 186 (5) Management of Mul
Page 203 and 204:
Epidemiology of Childhood Blindness
Page 205 and 206:
IS-SOS-SA 192 (6) Dyslexia Alkhudai
Page 207 and 208:
Page 209 and 210:
FP-COR-SA 196 (9) Study of Nomogram
Page 211 and 212:
FP-RET-SA 197 (8) RaScaL Study: A N
Page 213 and 214:
FP-CAT-SA 198 (5) Unilateral Diffra
Page 215 and 216:
Pediatric Cataract Surgery: Conquer
Page 217 and 218:
IS-GLA-SA 205 (7) Glaucoma and Opti
Page 219 and 220:
Age-Related Macular Degeneration an
Page 221 and 222:
IS-REF-SA 210 (5) Results of Lamell
Page 223 and 224:
Computer-Aided Diagnosis, Novel Ima
Page 225 and 226:
IS-LOW-SA 215 (4) Bitemporal Hemian
Page 227 and 228:
IC-SCS-SA 219 (4) I›ll Accept thi
Page 229 and 230:
FP-COR-SA 220 (9) Effect of Corneal
Page 231 and 232:
FP-EPI-SA 221 (7) The Cost-Effectiv
Page 233 and 234:
FP-CAT-SA 222 (5) The Results of To
Page 235 and 236:
IS-SSS-SA 229 (4) Inequality of Tra
Page 237 and 238:
Age-Related Macular Degeneration: N
Page 239 and 240:
IS-NEO-SA 235 (4) Automated Static
Page 241 and 242:
IS-EDU-SA 238 (2) A Checklist of St
Page 243 and 244:
IS-EVI-SA 241 (6) Glaucoma Eye Drop
Page 245 and 246:
FP-IMG-SA 243 (9) Usefulness of Ang
Page 247 and 248:
FP-COR-SA 244 (10) Immunocytochemic
Page 249 and 250:
FP-RET-SA 245 (11) Two-photon Excit
Page 251 and 252:
What Will You Do? Sat 18 Feb 15:30
Page 253 and 254:
Abstracts Sunday 19 February
Page 255 and 256:
IS-GLA-SU 253 (4) Efficacy of Ologe
Page 257 and 258:
Retina Hot Topics Sun 19 Feb 8:30 -
Page 259 and 260:
FP-OCP-SU 257 (6) Eyelid Retraction
Page 261 and 262:
Free Paper: Oncology Sun 19 Feb 8:3
Page 263 and 264:
FP-ONC-SU 260 (11) Effect of Intrav
Page 265 and 266:
IS-WFS-SU 263 (4) How Can we Increa
Page 267 and 268:
IS-UVE-SU 266 (4) Glaucoma Surgery
Page 269 and 270:
FP-COR-SU 268 (6) Intrastromal Amph
Page 271 and 272:
FP-TRA-SU 269 (4) The role of Amylo
Page 273 and 274:
FP-REF-SU 270 (2) Refractive and Ab
Page 275 and 276:
FP-REF-SU 270 (11) Outcome of Simul
Page 277 and 278:
Wound Management and Bleb Problems
Page 279 and 280:
IS-RET-SU 281 (5) Beneficial of Dir
Page 281 and 282:
IS-STR-SU 284 (3) Genetics and Chil
Page 283 and 284:
IS-ONC-SU 285 (19) Orbit: 17 Year O
Page 285 and 286:
IS-WFS-SU 288 (6) Residency Program
Page 287 and 288:
FP-CLR-SU 290 (5) Heritability of P
Page 289 and 290:
IS-SCS-SU 292 (4) Minimally Invasiv
Page 291 and 292:
FP-COR-SU 293 (8) Three-Year Result
Page 293 and 294:
FP-RET-SU 294 (6) Clinical and Opti
Page 295 and 296:
FP-OCP-SU 295 (4) Long term follow-
Page 297 and 298:
Corneal Specular Microscopy Sun 19
Page 299 and 300:
New Therapeutic Approaches in Glauc
Page 301 and 302:
Diagnosis and Management of Retinop
Page 303 and 304:
IS-REF-SU 308 (10) Is Pseudophakia
Page 305 and 306:
IS-TEC-SU 311 (6) New Developments
Page 307 and 308:
IS-CLR-SU 315 (3) The Oliver Dabezi
Page 309 and 310:
FP-IMG-SU 317 (6) Nonmy Driatic Scr
Page 311 and 312:
FP-COR-SU 318 (3) Collagen Crosslin
Page 313 and 314:
FP-COR-SU 318 (11) Evidence of Impr
Page 315 and 316:
FP-WFS-SU 319 (8) Cataract Surgery
Page 317 and 318:
FP-CAT-SU 320 (5) Refractive Predic
Page 319 and 320:
FR-CAT-SU 325 (8) Implants Phaques
Page 321 and 322:
Cornea and Eye Banking in India Sun
Page 323 and 324:
Complex and Difficult Management De
Page 325 and 326:
Prognostic Biopsy of Uveal Melanoma
Page 327 and 328:
IS-WFS-SU 337 (3) The Role of Natio
Page 329 and 330:
IS-PHA-SU 340 (3) Managing the Infl
Page 331 and 332:
FP-HIS-SU 341 (7) Supporting an Eme
Page 333 and 334:
FP-COR-SU 342 (5) Efficacy of Intac
Page 335 and 336:
FP-ONC-SU 343 (2) Large Basal Cell
Page 337 and 338:
Free Paper: Refractive Surgery Sun
Page 339 and 340:
Using Computers for Managing Patien
Page 341 and 342:
Abstracts Monday 20 February
Page 343 and 344:
IS-GLA-MO 352 (3) What Tests are Mo
Page 345 and 346:
IS-RET-MO 354 (3) Summary of DRCR.n
Page 347 and 348:
IS-OCP-MO 356 (5) Refining the Outc
Page 349 and 350:
FP-REF-MO 357 (10) Using Objective
Page 351 and 352:
IS-TEC-MO 360 (6) Signaling Pathway
Page 353 and 354:
IS-STR-MO 363 (6) Adaptive Optics i
Page 355 and 356:
FP-WFS-MO 366 (3) Compliance of Spe
Page 357 and 358:
Page 359 and 360:
FP-COR-MO 367 (10) Toxic Epidermal
Page 361 and 362:
FP-TRA-MO 368 (8) Prospective Study
Page 363 and 364:
FP-CAT-MO 369 (5) Outcomes After Cr
Page 365 and 366:
Education Without Borders: The Futu
Page 367 and 368:
FP-GLA-MO 374 (6) Survey of Glaucom
Page 369 and 370:
IS-COR-MO 376 (2) Endothelial Cell
Page 371 and 372:
FP-TRA-MO 377 (5) Assessment of Fac
Page 373 and 374:
FP-RET-MO 378 (2) A Detailed Evalua
Page 375 and 376:
FP-RET-MO 378 (10) Correlation Betw
Page 377 and 378:
Free Paper: Strabismus Mon 20 Feb 1
Page 379 and 380:
FP-STR-MO 381 (9) Immediate Post-Op
Page 381 and 382:
IS-PAT-MO 383 Clinicopathological C
Page 383 and 384:
FP-EPI-MO 384 (9) Eye Care Programm
Page 385 and 386:
FP-NEO-MO 386 (5) Toxoplasma Neuror
Page 387 and 388:
Contact Lens - Newton Kara José Sy
Page 389 and 390:
FP-COR-MO 389 (4) Calcium Channels
Page 391 and 392:
FP-EPI-MO 390 (2) The Distribution
Page 393 and 394:
FP-EPI-MO 390 (10) Optical Quality
Page 395 and 396:
FP-OCP-MO 391 (8) Fat Transfer for
Page 397 and 398:
Free Paper: Retina - Medical Mon 20
Page 399 and 400:
FP-RET-MO 396 (9) Results of the Ph
Page 401 and 402:
FP-GLA-MO 397 (8) A New Approach fo
Page 403 and 404:
FP-COR-MO 398 (5) Visual Results of
Page 405 and 406:
FP-TRA-MO 399 (3) Role of Ophthalmi
Page 407 and 408:
FP-REF-MO 400 (3) Using a Small Ape
Page 409 and 410:
FP-REF-MO 400 (11) The KAMRA Intrac
Page 411 and 412:
FP-OCP-MO 401 (9) To Describe a Nov
Page 413 and 414:
FP-CAT-MO 402 (7) Three-Port MICS (
Page 415 and 416:
Free Paper: Oncology Mon 20 Feb 13:
Page 417 and 418:
FP-ONC-MO 404 (9) Plaque Therapy fo
Page 419 and 420:
FP-TEC-MO 405 (6) Teleophthalmology
Page 421 and 422:
FP-EPI-MO 406 (4) Prevalence and As
Page 423 and 424:
Free Paper: Prevention of Blindness
Page 425 and 426:
FP-WFS-MO 407 (9) RAAB Surveys: A T
Page 427 and 428:
FP-EDU-MO 408 (6) Effect of Univers
Page 429 and 430:
FP-IMM-MO 409 (3) TNF- a and Glycat
Page 431 and 432:
FP-IMM-MO 409 (11) Th1/Th2 Cytokine
Page 433 and 434:
FP-UVE-MO 410 (8) Ocular Features i
Page 435 and 436:
FP-COR-MO 411 (5) Tunnel Infection
Page 437 and 438:
FP-STR-MO 412 (3) A Relationship be
Page 439 and 440:
Workshop on e-Learning Tools Mon 20
Page 441 and 442:
Video Cataract VI-CAT-01 Alice in V
Page 443 and 444:
I-CAT-16 Microincisional Surgery of
Page 445 and 446:
VI-CAT-30 CATARACT SURGERY ‹REVOL
Page 447 and 448:
VI-CAT-48 A NEW PHACO NEEDLE Joseph
Page 449 and 450:
VI-CAT-62 Challenges in Intraocular
Page 451 and 452:
VI-CAT-76 Primary Posterior Capsulo
Page 453 and 454:
VI-COR-14 A video demonstrating ret
Page 455 and 456:
Ophthalmic Education VI-EDU-01 Lase
Page 457 and 458:
VI-GLA-12 Combined cataract and Gla
Page 459 and 460:
Low Vision and Rehabilitation VI-LO
Page 461 and 462:
VI-OCP-11 Lateral tarsal STRIP Unde
Page 463 and 464:
Oncology VI-ONC-01 Ocular Surface S
Page 465 and 466:
Refractive Surgery VI-REF-01 Persis
Page 467 and 468:
VI-RET-10 Is process of epiretinal
Page 469 and 470:
VI-RET-26 Nanophthalmic uveal effus
Page 471 and 472:
Eye Trauma and Emergencies VI-TRA-0
Page 473 and 474:
PO-CAT-06 Outcomes of Unilatteral T
Page 475 and 476:
PO-CAT-15 Cataract Surgery Outcome
Page 477 and 478:
PO-CAT-26 Piggy Back ioil Implantat
Page 479 and 480: PO-CAT-34 The Results of OZIL IP So
Page 481 and 482: PO-CAT-43 Influence of Emoxipin on
Page 483 and 484: PO-CAT-52 Vector Analysis of Astigm
Page 485 and 486: PO-CAT-62 Akreos Adapt Calcificatio
Page 487 and 488: PO-CAT-71 A New Era in Manual SICS
Page 489 and 490: PO-CAT-79 The New Helical Composite
Page 491 and 492: PO-CLR-04 Therapeutic Use of Fluoro
Page 493 and 494: Evidence Based Ophthalmology PO-EVI
Page 495 and 496: PO-COR-8 Corneal Microsporidiosis S
Page 497 and 498: PO-COR-17 Documentation of Keratoco
Page 499 and 500: PO-COR-26 Corneal Collagen Crosslin
Page 501 and 502: PO-COR-34 Results of Descemets Stri
Page 503 and 504: PO-COR-44 Comparison of Rose Bengal
Page 505 and 506: PO-COR-54 Corneal Cross-Linking as
Page 507 and 508: PO-COR-65 Tpical tacrolimus as a tr
Page 509 and 510: PO-COR-74 Extensive bilateral corne
Page 511 and 512: PO-COR-85 Short Term Visual Outcome
Page 513 and 514: PO-COR-94 Successful treatment of f
Page 515 and 516: PO-COR-103 Descemet´s membrane det
Page 517 and 518: PO-COR-114 ANATOMICAL AND FUNCTIONA
Page 519 and 520: PO-COR-122 Post-keratoplasty emerge
Page 521 and 522: PO-COR-130 Fungal keratitis: a UKMM
Page 523 and 524: PO-TRA-08 Epidemiology of Canalicul
Page 525 and 526: PO-TRA-19 An infant case of traumat
Page 527 and 528: PO-GLA-07 Comparison of Optic Nerve
Page 529: PO-GLA-15 Novel, minimally invasive
Page 533 and 534: PO-GLA-31 Epidemiology of Clinical
Page 535 and 536: PO-GLA-40 Family history a vital ri
Page 537 and 538: PO-GLA-50 The Measurement of the In
Page 539 and 540: PO-GLA-60 EMERGING PATTERNS AND FAC
Page 541 and 542: PO-GLA-69 Angle closure glaucoma in
Page 543 and 544: PO-GLA-78 Efficacy of needling with
Page 545 and 546: PO-IMM-02 Symptomatic behavior of c
Page 547 and 548: PO-IMM-13 Identification of Autoant
Page 549 and 550: Low Vision and Rehabilitation PO-LO
Page 551 and 552: PO-NEO-06 Familial occurrence of op
Page 553 and 554: PO-NEO-18 Myastenia Gravis: 2 Cases
Page 555 and 556: PO-TEC-05 Polyurethane biodegradabl
Page 557 and 558: PO-IMG-04 EVALUATION OF TEAR FILM Q
Page 559 and 560: PO-IMG-13 A Prospective Study to Ac
Page 561 and 562: PO-IMG-22 Biometry of the anterior
Page 563 and 564: PO-OCP-10 Basics of external dacryo
Page 565 and 566: PO-OCP-19 Surgical Outcomes of Pedi
Page 567 and 568: PO-OCP-27 Morphological changes of
Page 569 and 570: PO-OCP-38 Demographic of Patients w
Page 571 and 572: PO-OCP-48 Acquired severe contracte
Page 573 and 574: PO-OCP-58 effectiveness of silicone
Page 575 and 576: PO-OCP-68 ANOPHTALMIA -ABOUT three
Page 577 and 578: PO-ONC-06 Clinical Profile, Managem
Page 579 and 580: PO-ONC-15 Use of Mitomycin-C and In
Page 581 and 582:
PO-ONC-23 CONJUNCTIVAL TUMORS(about
Page 583 and 584:
PO-ONC-33 Orbital Recurrence follow
Page 585 and 586:
Ophthalmic Epidemiology PO-EPI-01 P
Page 587 and 588:
PO-EPI-11 Tear Function in an Irani
Page 589 and 590:
PO-EPI-19 The Annual Direct Cost of
Page 591 and 592:
PO-PAT-02 EFFECTS OF X RADIATION ON
Page 593 and 594:
PO-PED-06 A novel phenotype of juve
Page 595 and 596:
PO-PED-16 Retinoblastoma Masqueradi
Page 597 and 598:
PO-PED-26 Prevalence of RDS periphe
Page 599 and 600:
PO-PED-35 Managing Peadiatric Catar
Page 601 and 602:
PO-WFS-03 Prevalence and causes of
Page 603 and 604:
PO-WFS-13 Surgical Expedition to Gh
Page 605 and 606:
PO-REF-06 Improving the predictabil
Page 607 and 608:
PO-REF-16 Refractive and Optical Qu
Page 609 and 610:
PO-REF-25 Nodular Episcleritis afte
Page 611 and 612:
PO-REF-35 Comparative electron micr
Page 613 and 614:
PO-RET-04 Examining Recalcitrant Di
Page 615 and 616:
PO-RET-13 Sterile Endophthalmitis a
Page 617 and 618:
PO-RET-21 Diagnostic and Management
Page 619 and 620:
PO-RET-30 Red blood cell targeted c
Page 621 and 622:
PO-RET-40 Is Fundus fluorescein ang
Page 623 and 624:
PO-RET-49 Isotretinoin associated t
Page 625 and 626:
PO-RET-61 The outcome of intravitre
Page 627 and 628:
PO-RET-70 TRAINING AND ACCREDITATIO
Page 629 and 630:
PO-RET-79 Valsalva Retinopathy duri
Page 631 and 632:
PO-RET-89 Hypoxia-inducible factor-
Page 633 and 634:
PO-RET-98 BRAO - It is never too la
Page 635 and 636:
PO-RET-106 Retinal Manifestations o
Page 637 and 638:
PO-RET-116 Camp Approach to Diabeti
Page 639 and 640:
PO-RET-125 Idiopathic Macular Telan
Page 641 and 642:
PO-RET-134 Acute Retinal Necrosis A
Page 643 and 644:
PO-RET-144 Scleral Buckling Surgery
Page 645 and 646:
PO-RET-152 Comparison of internal l
Page 647 and 648:
PO-RET-161 Optical coherence tomogr
Page 649 and 650:
PO-RET-171 Management of recurrent
Page 651 and 652:
PO-RET-180 Visual and surgical outc
Page 653 and 654:
PO-RET-190 Pediatric Vitrectomy in
Page 655 and 656:
PO-RET-200 23 Gauge Pars Plana Vitr
Page 657 and 658:
Strabismus PO-STR-01 Evaluation of
Page 659 and 660:
PO-STR-12 Congenital Superior Obliq
Page 661 and 662:
PO-STR-23 Quality of Life and Cost-
Page 663 and 664:
PO-UVE-03 Recurrence of presumed bi
Page 665 and 666:
PO-UVE-12 SIL2R, Neopterin and angi
Page 667 and 668:
PO-UVE-23 Clinical features of pati
Page 669 and 670:
PO-UVE-32 Ocular tuberculoma with a
Page 671 and 672:
Akbarzadeh Siamak : 164 Akcetin Tul
Page 673 and 674:
Ansari Astaneh mohammad reza : 555
Page 675 and 676:
Bi Xiaoping : 61 Bialasiewicz Alexa
Page 677 and 678:
Constable Ian : 177 Constable Ian :
Page 679 and 680:
El-Sebaity Dalia M : 236 Elserogy H
Page 681 and 682:
Goes Frank : 186 Gogate Parikshit :
Page 683 and 684:
Honavar Santosh : 38, 98, 110, 117,
Page 685 and 686:
Kaminska Anna : 395, 474 Kamlesh :
Page 687 and 688:
Kumar Mahesh : 376 Kumar Najith : 6
Page 689 and 690:
Markuszewska Anna : 600 Markuszewsk
Page 691 and 692:
Myint Kay Thi : 417 Myrowitz Elliot
Page 693 and 694:
Pang Calvin : 118, 211 Pangarkar An
Page 695 and 696:
Reddy J. K. : 181 Reddy Jagadesh :
Page 697 and 698:
Shaarawy Ashraf : 86, 207, 239 Shaa
Page 699 and 700:
Sullivan Paul : 22, 66 Sullivan Tim
Page 701 and 702:
Vetrugno Michele : 88 Victoria Dari
show all

Table of Contents - WOC 2012

Create successful ePaper yourself

Delete template?

Save as template?